Bhiman, Jinal N.
Richardson, Simone I.
Lambson, Bronwen E.
Kgagudi, Prudence
Mzindle, Nonkululeko
Kaldine, Haajira
Crowther, Carol
Gray, Glenda
Bekker, Linda-Gail
,
Koen, Anthonet
Fairlie, Lee
Fouche, Leon
Bhorat, Qasim
Dheda, Keertan
Tameris, Michele
Masilela, Mduduzi
Hoosain, Zaheer
Singh, Nishanta
Hanley, Sherika
Archary, Moherndran
Louw, Cheryl
Grobbelaar, Coert
Lalloo, Umesh
Joseph, Natasha
Kruger, Gertruida
Shinde, Vivek
Bennett, Chijioke
Glenn, Gregory M.
Madhi, Shabir A.
Moore, Penny L.
Funding for this research was provided by:
Novavax
Bill and Melinda Gates Foundation
South African Research Chairs Initiative of the Department of Science and Innovation and National Research Foundation of South Africa
South African Medical Research Council
Centre for the AIDS Programme of Research in South Africa
Article History
Received: 9 September 2022
Accepted: 5 January 2023
First Online: 21 January 2023
Competing interests
: Dr. Shinde reports being employed by and owning shares in Novavax; Dr. Q. Bhorat, receiving grant support from Wits Health Consortium, Regeneron Pharmaceuticals, GSK, Avillion, Sanofi, Novo Nordisk, and Novavax; Dr. Fouche, receiving grant support from BioNTech; Dr Bennet reports being employed by Novavax; Dr. Glenn, being employed by and owning stock in Novavax and owning stock in RA Capital; and Dr. Madhi, receiving grant support, paid to his institution, from Pfizer and GSK. All remaining authors have not reported any conflicts of interest.